EnsiliTech Secures £4.5M In Pre-Seed Round

The funding will support the company’s mission to revolutionise how life-saving medicines are stored and transported around the world.

Currently, most biopharmaceuticals rely on a decades-old "cold chain" a global refrigeration and freezing system that is both costly and energy-heavy. When this system fails, it costs the industry an estimated £26 billion each year.

In lower-income countries, the situation is even more severe: the World Health Organization (WHO) reports that up to 50% of vaccines are lost due to cold chain failures, putting millions at risk of missing vital treatment.

Read Also - Yottar Raises $1M In Pre-Seed Funding

EnsiliTech aims to eliminate these challenges with its Ensilication technology, which stabilises vaccines, antibodies and other biologics at room temperature, withstanding heat up to 50°C. By removing the need for constant refrigeration, the company is making medicines more accessible, streamlining global distribution and reducing environmental impact. Their innovation holds the potential to deliver critical treatments to even the most remote and underserved regions.

Dr.Asel Sartbaeva, co-founder and CEO of EnsiliTech, explained: Our mission is to ensure that life-saving medicines and vaccines reach everyone, everywhere, regardless of infrastructure or geography. By eliminating the need for refrigeration our technology significantly reduces supply chain costs and drug waste while also lowering the environmental impact of pharmaceutical distribution.

This investment marks a significant step forward for the team, and we’re thrilled to have the backing of partners who share our vision for a more equitable and sustainable future in global healthcare.

Ensilication is a breakthrough technology that coats biological materials like vaccines and antibodies with a microscopic layer of silica, the same natural substance found in sand. This protective coating forms a custom-fit shell around each active ingredient keeping it stable without the need for refrigeration or freezing.

The silica “cage” preserves the integrity of the biological material, protecting it from changes in temperature or humidity. Since silica is biocompatible, inert and inexpensive, it’s safe and practical for medical use. When it’s time to use the medicine, the silica shell naturally breaks away leaving the original ingredient intact and fully effective.

This innovative approach means vaccines and other critical treatments can be stored and transported at room temperature, opening the door to broader global access especially in areas with limited refrigeration infrastructure.

EnsiliTech’s £4.5M seed round was led by Eos Advisory, with continued support from Calculus Capital. Other investors included Empirical Ventures, Fink Family Office, QantX, Angel Investors Bristol (AIB), HERmesa, Penn Park Capital, chANGELS, and various individual angels.

Anne Muir, Director of Portfolio at Eos, said: EnsiliTech has the technology to transform how vaccines and other therapeutics are transported and stored. Reducing waste, lowering costs, and vastly improving health outcomes globally, this kind of science and its scale of potential sit at the core of our investment thesis at Eos.

Elizabeth Klein-Edmonds, Investment Director at Calculus, shared her enthusiasm about supporting EnsiliTech during this pivotal phase of growth. She highlighted the company’s unique, patented platform, which she said is already gaining significant commercial traction. She added:

The potential applications for vaccines and antibody treatments are transformative, with the ability to improve accessibility and enhance patient care across global health systems. We look forward to collaborating with Asel and her talented team, whose deep market understanding, and expertise position them for exceptional success.

Johnathan Matlock, Co-founder of Empirical Ventures, said EnsiliTech is a great example of their evidence-based investment approach. In just three years, the company has progressed from academic research to active licensing discussions, all while systematically addressing technical, regulatory, and commercial risks. He shared:

We believe EnsiliTech has the potential to become the category leader in biologics thermostabilisation, unlocking new global markets for vaccines, mRNA therapies and antibodies. Our conviction is grounded in data, including demonstrated technical efficacy early in vivo safety validation, and live commercial negotiations with billion euro pharmaceutical partners. This is an investment that offers the potential for both strong financial returns and a substantial global health impact.

The new funding will help accelerate the adoption of EnsiliTech’s technology by enabling proof of concept projects for both current and future biopharmaceuticals. The company plans to expand its team and upgrade its facilities to increase capacity while also investing in essential validation studies to integrate Ensilication into pharmaceutical manufacturing workflows.

EnsiliTech is led by a predominantly female leadership team and R&D team, reflecting its focus on diversity, inclusion and scientific innovation. This commitment also drew investment from HERmesa, a group dedicated to supporting female-led ventures.